Corpus Intelligence DCF — UNIVERSITY OF WASHINGTON MED CTR 2026-04-26 02:15 UTC
DCF — UNIVERSITY OF WASHINGTON MED CTR
Enterprise Value: $-4.4B
🛡️ Public data only — no PHI permitted on this instance.
$-4.4B
Enterprise Value
$-1.4B
PV of Cash Flows
$-3.1B
PV of Terminal Value
$-4.9B
Terminal Value
10.0%
WACC
2.5%
Terminal Growth

Cash Flow Projections

PROJ
YearRevenueEBITDAMarginFCFPV(FCF)
Year 1$2.1B$-288.9M-14.0%$-376.8M$-342.6M
Year 2$2.1B$-276.1M-13.0%$-366.7M$-303.1M
Year 3$2.2B$-262.4M-12.0%$-355.7M$-267.2M
Year 4$2.3B$-258.9M-11.0%$-355.0M$-242.5M
Year 5$2.3B$-260.8M-11.0%$-359.8M$-223.4M

Interpretation

INT

At a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-4.4B. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.

Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.

Assumptions

ASSM
revenue base$2.0B
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.14404446671302928
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5